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SUMMARY - The authors describe a family with three members affected by glioblastoma. The proband patient, 
a 7 year-old girl, developed a rare complication, a pulmonary metastasis. Chromosomal analysis of her peripheral 
blood lymphocytes showed a normal karyotype (46, XX), without structural abnormalities. Cytogenetic study 
of the tumor cells disclosed several abnormalities: 46, XX, 7q - / 46, XX, -2, 4p-, 7p-, +15/ 46, XX. Some 
aspects about genetics of glial neoplasms are discussed. 
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Glioblastoma familiar 
RESUMO - Os autores descrevem uma família com três membros portadores de glioblastoma. A paciente 
probanda, uma menina de 7 anos, apresentou metástase pulmonar. A análise cromossômica dos linfócitos 
periféricos revelou um cariótipo normal (46, XX). Estudo citogenético das células tumorais mostrou várias 
anormalidades: 46, XX, 7q- / 46, XX, -2,4p-, 7p-, +15 / 46, XX. Alguns aspectos sobre oncogênese e citogenética 
das neoplasias gliais são discutidos. 
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The occurrence of glioblastoma in more than one member of a family is uncommon 4 ' 6 , 9 , 1 2 1 4 , 1 8 . 
Some cases of familial gliomas are associated with genetic syndromes, such as tuberous sclerosis, 
neurofibromatosis, von Hippel-Lindau, colonic polyposis (Turcot's syndrome) , and hepatic focal 
nodular hyperplasia, whereas other cases occur as isolated findings16,17. Cytogenetic analyses of the 
central nervous system (CNS) have revealed some relatively specific chromosomal abnormalities. 
For example, deletions of chromosome 22 have been frequently observed in meningiomas and in 
neurofibromatosis type I I 1 6 1 7 . Neuroblastomas often have deletions of lp , and when their cells show 
an amplified oncogene, N-myc, a poor clinical outcome can be predicted 2 3. Frequent allelic losses of 
chromosomes 9p, 10, 17p, 19, and 22q are present in some glial tumors 1 5 . 
There are few reports of cytogenetic analysis in familial cases 6. We report a patient in a family 
with several members having glioblastoma and the cytogenetic findings in this patient. 
FAMILY DESCRIPTION 
The heredogram is shown in Figure 1. The proband patient (IV-2), a 7 year-old girl, complained 
of headaches and vomiting since January 1988. At this time, neurological examination disclosed 
bilateral papilledema, and a CT scan two weeks later showed a left occipital tumor lesion. She 
underwent surgery, with radical excision of the tumor. Histological examination showed a 
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glioblastoma. The operation was followed by radiotherapy and chemotherapy. In October 1989, a 
chest X-ray showed a nodular lesion in the right lung (Fig 2). The lesion was totally removed 
through a thoracotomy. Pathological examination disclosed glioblastoma. Immunohistochemical 
study of the brain and lung lesions showed positive reaction for GFAP, S-100, and focal reaction to 
enolase (Fig 3). In December 1989, the cerebral lesion recurred and she had surgery again. The 
patient died in May 1990 due to neoplastic recurrence. The brother of the proband (IV-1), 7 years-
old, had a quite similar clinical picture, and a tumoral lesion was detected in the right frontal lobe. 
He was operated on in November 1986, followed by radiotherapy, and died in January 1988. 
Histological examination disclosed glioblastoma. The father of these two children (III-3) had a 
cerebral tumor lesion diagnosed by CT-scan when he was 30 years-old. He was operated on twice 
(December 1987 and January 1988), and died in December 1988, after radiotherapy and chemotherapy. 
The histological diagnosis was also glioblastoma. His father (II-2), the proband's grandfather, died 
in 1968, with the diagnosis of brain tumor. The histological slides could not be reviewed. Three 
other members of this family died of malignant neoplasms in other areas: breast, larynx, colon 
(members II-5, II-6, and III-5, respectively). 
CYTOGENETIC STUDY 
Cytogenetic study of peripheral blood lymphocytes of the proband patient was normal (46, 
XX). Culture of tumoral cells with cytogenetic analysis disclosed several structural chromosomal 
abnormalities: 46, XX, 7q -146 , XX, -2, 4p-, 7p-, +15 146, XX. 
COMMENTS 
Our patients present some unique features: 1) Other members of the proband's family are 
affected by the same histological type of neuroepithelial tumor of the CNS, suggesting an autosomal 
dominant genetic transmission; 2) The peak age incidence of glioblastoma is between 45 and 55 
years; it is decidedly rare before 30 1 7 ; and 3) Extraneural metastasis are uncommon with all glioma 
types; nevertheless, glioblastoma is the most common tumor related with remote metastases, especially 
to the lungs. Russell and Rubinstein reviewed 116 cases of different types of glioma with extraneural 
metastases, and glioblastoma was responsible for 41.4% of the cases 1 7 . 
Several cytogenetic abnormalities including recurrent site-specific or duplication, chromosomal 
translocations, deletions and additions are identified in some primary brain tumors"-20. Some of these 
structural chromosome abnormalities have been related with the aberrant expression of a proto-
oncogene. Proto-oncogenes encode proteins that regulate cellular replication and cellular 
differentiation 1 9 2 3 . A proto-oncogene may change its function and become a transforming gene, so-
called oncogene. The activated oncogene directs the synthesis of qualitatively or quantitatively 
abnormal proteins that are the real effector of neoplastic transformation. Some examples of oncogenes 
identified in glioblastoma are N-myc, c-sis, c-erb-B and rosX9Ji. Proto-oncogenes c-erb-B and c-sis 
are respectively mapped to chromosomes 7 and 22 2 0 . Peptide growth factors are also important for 
the control of cell growth and differentiation. Proto-oncogene c-erb-B encodes the epidermal growth 
factor receptor (EGFR) and c-sis encodes for one of the polypeptides of platelet-derived growth 
factor (PDGF) 1 9 ' 2 0 ' 2 3 . Interestingly, overexpression of EGFR has been reported in primary brain tumors, 
including glioblastoma 1 9. Furthermore, production of high amounts of PDGF occurs in some glioma 
cell lines 2 0 ' 2 2 . 
Single structural rearrangement has not been consistently related to specific histological types 
of human gliomas. It is conceivable that they may be a secondary event in the evolution of the tumor 
system rather than a primary event 2 0. 
Nevertheless, some relatively specific patterns of chromosome gains and losses have been 
observed in both astrocytomas and malignant gliomas. Frequent allelic losses of chromosomes 9p, 
10, 17p, 19, and 22q were identified 1 1 1 5 . Missing sequences of chromosome 10 occur in 53-97% of 
glioblastoma cases. Bigner et al 2 detected statistically significant abnormalities of near-diploid tumor 
such as gains of whole copies of chromosome 7, losses of chromosomes 10, structural abnormalities 
of 9p and 19q, and the presence of double minutes in 43 cases of glioblastomas. Other numerical 
changes include losses of chromosomes 22 and sex chromosomes (gonosomes) 1. A tumor supressor 
gene located on chromosome 17, p53, is frequently affected in many human tumors, including 
malignant astrocytomas. In fact,p53 mutations were found in malignant astrocytomas stages but not 
in low-grade astrocytoma 7. Fults et al. 7 found loss of heterozygosity on chromosome 10 and p53 
mutation only in patients with glioblastoma (22%), suggesting that these genetic changes may 
accumulate during astrocytoma progression. Litofsky et al. 1 3 detected p53 mutations in 15% of low 
grade astrocytomas, while this finding occurred in 38% of glioblastomas out of an adult population. 
However, in pediatric cases, p53 mutations probably does not play a major role in oncogenesis. 
Clonal expansion of p53 mutant cells 2 1, specific abnormalities on chromosome 17, and chromosome 
10 changes 3 1 0 may influence progression from astrocytoma to glioblastoma. Studies using DNA 
markers that detect restriction fragment length polymorphism (RFLP) and polymerase chain reaction 
- single-strand conformation polymorphisms analysis (PCR-SSCP) might be the only way to detect 
such abnormalities in our case. 
We could find only one previous report of two siblings with glioblastoma with chromosome 
studies 6. In the first case, numerical and structural abnormalities including translocation between 
chromosomes 11 and 14, often seen in a tetraploid version of the basic karyotype, were detected. 
The tumor of the second case contained cells with no numerical and structural abnormalities. 
Those findings are quite different from our case. Discrepancy of cytogenetic findings from 
different reports may be the result of random sampling of the surgical specimen. Furthermore, different 
regions of the same tumor lesion may or may not show chromosomal abnormalities 2 0. Shapiro 
demonstrated regional karyotypic heterogeneity in glioblastomas resected almost in toto 2 0 . The 
observation of different cytogenetic abnormalities that are not observed in all glial tumors may also 
suggest that tumors with a common histopathological identity may have different molecular genetic 
profiles. 
REFERENCES 
1. Bigner SH, Bjervig R, Laerum OD. DNA content and chromosomal composition of malignant human 
gliomas. Neurol Clin 1985, 3:769-784. 
2. Bigner SH, Mark J, Burger PC, Mahaley MS, Bullard DE Jr , Muhlbaier LH, Bigner DD. Specific 
chromosomal abnormalities in malignant human gliomas. Cancer 1988, 88:405-411. 
3. Cavenee WK, Corable HJ, James CD. Molecular genetics of human cancer predisposition and progression. 
Mutat Res 1991, 274:199-202. 
4. Challa VR, Goodman HO, Davis CH Jr. Familial brain tumors: studies of two families and review of recent 
literature. Neurosurgery 1983, 12:18-23. 
5. Deimling A, Louis DN, Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor supressor 
gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. 
Cancer Res 1992, 52:4277-4279. 
6. Duhaime AC, Bunin G, Sutton L, Rorke LB, Packer RJ. Simultaneous presentation of glioblastoma 
multiforme in siblings two and five years old: case report. Neurosurgery 1989, 24:434-439. 
7. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity 
on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992, 52:674-679. 
8. Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS. Chromosome abnormalities in pediatric 
brain tumors. Cancer Res 1988, 48:175-180. 
9. Hardman PDJ, Bell J, Whittle IR, Gregor A. Familial glioma: a report of glioblastoma in identical twins and 
oligo-astrocytoma in siblings. Br J Neurosurg 1989, 3:709-715. 
10. James CD, Carlbom E, Dumansky JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK. Clonal genomic 
alterations in glioma malignancy stages. Cancer Res 1988, 48:5546-5551. 
11. James CD, He J, Car lbom E, Nordenskjold M, Cavenee WK, Collins P. Chromosome 9 delet ion 
mapping reveals interferon alfa and interferon beta-1 gene deletions in human glial tumors. Cancer 
Res 1991, 51:1684-1688. 
12. Kaufman HH, Brisman R. Familial gliomas: report of four cases. J Neurosurg 1972, 37:110-112. 
13. Litofsky NS, Hinton D, Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 
1994, 34:967-973. 
14. Maroun FB, Jacob JC, Heneghan WD, Mangan MA, Russel NA, Ali SK, Murray GP, Clarke A. Familial 
intracranial gliomas. Surg Neurol 1984, 22:76-77. 
15. Ransom DT, Ritland SR, Jenkins RB, Scheithauer B, Kelly PJ, Kimmel DW. Loss of heterozygosity studies 
in human gliomas. Proc Am Assoc Cancer Res 1991, 32:302. 
16. Rubenstein AE, Korf BR. Neurofibromatosis: a handbook for patients, families, and health-care professionals. 
New York:, Thieme 1990, p99-110. 
17. Russell, DS, Rubinstein LJ. Pathology of tumours of the nervous system. Ed. 5. Baltimore: Williams & 
Wilkins, 1989, p1-57. 
18. Salcman M, Solomon L. Occurrence of glioblastoma multiforme in three generations of a cancer family. 
Neurosurgery 1984, 14:557-561. 
19. Schmidek HH. The molecular genetics of nervous system tumors. J Neurosurg 1987, 67:1-16. 
20 . Shapiro JR. Biology of gliomas: heterogeneity, oncogens, growth factors. Seminars Oncology 1986, 
13:4-15. 
2 1 . Sindransky D, Mikkelssen T, Schwechheimer K, Rosemblum ML, Cavenee W, Vogelstein B. Clonal 
expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992, 355:846-847. 
22. Westermark B, Nister M, Heldin C-H. Growth factors and oncogenes in human malignant glioma. Neurol 
Clin 1985, 3:785-799. 
23. Whittle IR. Oncogenes and neuro-oncology: review article. Br J Neurosurg 1989, 3:3-12. 
